Editorial

Defining the ideal patient for active surveillance in localized prostate cancer and the impact of active surveillance studies on clinical practice

• Ayhan Dirim
• Hakan Özkardes

Review

The developments in paradigm of prostate cancer in recent years

• Sertaç Yazici
• Halil Kizilöz
• Haluk Özen

PSA: past, today and tomorrow

• Levent Mert Günay
• Sertaç Yazici
• Haluk Özen

An update on palliative therapy in advanced prostate cancer

• Kaan Özdedeli
• Ugur Kuyumcuoglu

Current analysis of urinary biomarkers for prostate cancer

• Faruk Faruk
• Hakan Koyuncu

Prostate cancer, screening and diagnosis according to EAU and AUA 2013 updates and practical considerations

• Tu¨nkut Doganca
• Can Öbek

Can prostate cancer be prevented?

• Ilkan Yüksel
• Mustafa Kaplan

The role of surgery for high-risk prostate cancer

• Oktay Üçer
• Talha Mu¨ezzinoglu

Does inhibition of inflammation help in preventing prostate cancer ?

• Ali Ihsan Arik
• Ahmet Güdeloglu
• Cemil Uygur

Does the Future of Prostate Cancer Treatment Lie with Apoptotic Inducers?

• Dr. Ece Konaç
• Dr. Sinan Sözen

Lympadenectomy in prostate cancer

• Murat Kosan

The effect of trace elements in prostate cancer

• Ilker Çelen
• Feriye Senol
• Talha Müezzinoglu

Comparing outcomes of external radiotherapy modalities for prostate cancer

• Sefik Igdem

Has DNA methylation any impact in prostate cancer diagnosis?

• Buket Kosova
• Rukiye Özel
• Çagdas Aktan

In which fields intermittent androgen deprivation therapy can be used in 2014?

• Yasin Ceylan
• Bu¨lent Gu¨nlu¨soy

Active Surveillance: Treatment Modality that Expect Attention for Localized Prostate Cancer

• Tayyar Alp Özkan1
• Özdal Dillioglugil

A critical analysis of surgical curative treatments options in localised prostate cancer: open, laparoscopic, and robotassisted radical prostatectomy

• Ender Özden
• Yakup Bostanci
• Yarkin Kamil Yakupoglu

The role of 5a-reductase inhibitors on prevention and hormonal treatment of prostate cancer

• Bu¨lent Öztu¨rk
• Tufan Çiçek

Algorithmic approach to rising PSA after curative prostate cancer treatment

• Levent Mert Günay
• Sevket Tolga Tombul
• Bülent Akdogan

The influence of age on localized prostate cancer: Surgical result of patients over 70 years

• Erdal Benli
• Ali Ayyildiz

Could focal therapy in prostate cancer replace standard therapy in the future?

• Saadettin Y. Eskiçorapçi
• Cihan Toktas

Outstanding variations in the treatment of prostate cancer bone metastases

• Ibrahim Cu¨reklibatir

Neoadjuvant and adjuvant treatment modalities for prostate cancer

• Erkan Erkan
• Gökhan Toktas

How affected Active Surveillance the quality of life in low-risk localized prostate cancer?

• Ilker Çelen
• Sinharib Çitgez
• Talha Mu¨ezzinoglu

The importance of cellular androgenic hormonal mechanisms in treatment and progression of prostate cancer

• Bertrand Tombal

A New Era in Metastatic Prostate Cancer: “The Combination of Chemotherapy and Hormonal Treatment as Initial Treatment”

• İlker Tinay
• Levent Türkeri

Sentinel Lymph Node Biopsy in Lymphadenectomy for Prostate Cancer

• Cenk Acar
• Henk van der Poel

What is the evidence-based ideal treatment of clinical locally advanced (cT3) prostate cancer?

• Asif Yildirim
• Erem Kaan Basok

Is prostate cancer be screened according to Turkey data?

• Rahmi Gökhan Ekin
• Ferruh Zorlu

Active surveillance in low risk prostate cancer

• Ozan Bozkurt
• Ömer Demir

Hormonal treatment of metastatic prostate cancer: Today and future

• Hasan Soydan
• Kadir Baykal

Magnetic Resonance - Transrectal Ultrasound Fusion Guided Prostate Biopsy

• Ömer Burak Argun
• Can Öbek
• Ali Rıza Kural

Treatment options in low-intermediate risk prostate cancer

• Saadettin Yilmaz Eskiçorapçi
• Deniz Bolat

Immunotherapy in prostate cancer

• Murat Lekili

Nomograms for prostate cancer: which and when to use

• Saadettin Eskiçorapçi
• Deniz Bolat

Are there any treatment option for metastatic prostate cancer refractory to docetaksel?

• Yasar Bedük

Radiotherapy in low and intermediate-risk prostate cancer

• Deniz Yalman

Recommendations of Diet and Lifestyle in Prostate Cancer Patients

• Serdar Çelik

What is the best cutoff value of PSA in detection of prostate cancer

• Hakan Gemalmaz

What is the Approach to Negative Prostate Biopsies?

• Bora İrer
• Güven Aslan

What are the New Developments in Urinary, Serum and Tissue Biomarkers in Prostate Cancer?

• Hayrettin Şahin
• Mehmet Çetinkaya
• Hasan Deliktaş

NON-PSA biomarkers for prostate cancer

• Yarkin Kamil Yakupoglu
• Yakup Bostanci
• Ender Özden

Surgical treatment and/or radiotherapy in high risk prostate cancer

• Fatih Biçaklioglu
• Cenk Acar
• Sinan Sözen

Intermittent Versus Continuous Androgen Deprivation in Patients with Metastatic Prostate Cancer: Review

• Mehmet Yıldızhan
• Mehmet Dündar
• Mehmet Şirin Ertek

Evaluation of the Current Situation Tissue and Serum Biomarkers in Prostate Cancer

• Enis Kervancıoğlu
• Murat Koşan

Repeat prostate biopsy: who, when, how?

• Hayrettin Sahin

New treatment options for the castration resistant prostate cancer targeting the androgen synthesis and androgen receptor

• Yavuz Selim Süral
• Çag Çal

Focal Therapy for Prostate Cancer: Current Status of HIFU

• Tayyar Alp Özkan
• Saadettin Eskiçorapçı

New treatment options in castration resistant prostate cancer: enzalutamide and abiraterone acetate

• Bülent Akdogan

Radical Prostatectomy and Lymphadenectomy in the High-Risk Prostate Cancer: Surgical Technique, Functional and Oncologic Outcomes

• Hayrettin Şahin
• Hasan Deliktaş

Active surveillance for localized prostate cancer

• Ilker Tinay
• Levent Türkeri

New treatment options for the castration resistant prostate cancer: Cabazitaxel and Spileucel-T

• Gürbüz Görümlü
• Erdem Göker

New treatment options in castration resistant prostate cancer: denosumab, alpharadin

• Hakan Gemalmaz

Surgical technique of nerve sparing radical prostatectomy and periprostatic field anatomy

• Ali Cansu Bozaci
• Bülent Akdogan
• Haluk Özen

Treatment Approaches for Nonmetastatic Castration-Resistant Prostate Cancer

• Mehmet Yıldızhan
• Hakan Gemalmaz
• Mehmet Şirin Ertek

Relationship between active surveillance / watchfull waiting and quality of life in localised prostate cancer

• Ilker Çelen
• Yasin Ceylan

Current surgical approaches in local invasive prostate cancer: urologist approach

• Zafer Kozacioglu
• Bülent Günlüsoy

How shoud PSA repalse (rising PSA) be managed after radical prostatectomy? How should treatment algorithms be shaped?

• Ilker Çelen
• Murat Lekili

Active Surveillance in Prostate Cancer

• Volkan İzol
• Nebil Akdoğan

Prostate Biopsy 2014: TRUS, MRI/TRUS Fusion? Transrectal? Transperineal?

• Kaan Çömez
• Ozan Bozkurt
• Mehmet Uğur Mungan

Current treatment approaches in locally advanced prostate cancer: a radiation oncologist perspective

• Ömür Karakoyun Çelik

Radical prostatectomy indications and outcomes in the high-risk localised prostate cancer

• Hayrettin Sahin
• Hasan Deliktas

Management of recurrences after radiation therapy used for curative intent in prostate cancer

• Yilören Tanidir
• Levent Türkeri

Multiparametric MR in Prostate Cancer: General Practical Application Advices

• Seçil Mustafa
• Basara Işıl
• Altay Canan

Salvage radical prostatectomy for locally recurrent prostate cancer following primary radiotherapy

• Ali Cansu Bozaci
• Sertaç Yazici

AUA/ASTRO 2013 Guidelines for Adjuvant and Salvage Radiation Therapy After Prostatectomy: What are the Yields and the Changes?

• Deniz Yalman

Prostate cancer in the era of robotic surgery

• Çag Çal

‘Nanotechnology Applications’ in the Treatment of Prostate Cancer

• Ali Furkan Batur
• Kerem Gencer Kutman
• Mustafa Suat Bolat

Immunotherapy for the treatment of castration resistant prostate cancer: sipuleucel-T

• Güven Aslan

Active Surveillance-Factors Affecting the Treatment Decision: 3M: “Marker”, “Mapping”, “MRI”

• Ender Özden
• Mehmet Necmettin Mercimek

New treatment stragies in metastatic castration resistant prostate cancer: Re-Docetaxel, Abiraterone asetate, Cabazitaxel, MDV 3100

• Sitki Ün
• Ferruh Zorlu

Information about Prostate Cancer for Urologist: Ga-68 Prostate Specific Membrane Antigen Positron Emission Tomography/Computed Tomography Scintigraphy

• Levent Kabasakal

Rising Psa After Radical Prostatectomy: Radiotherapy in High Risk Group: Early? Late?

• Gül Alço
• Sefik İğdem

Active Surveillance in Prostate Cancer: Can We Expand the Indications?

• Hacı Murat Akgül
• Asgar Garayev
• İlker Tinay

Update in the management of skeletal related events for metastatic prostate cancer: Denosumab, Alfaradin

• Serdar Çelik
• Ugur Mungan

The significance of tertiary Gleason pattern in prostate cancer

• H. Hüseyin Tavukçu
• Polat Türker

Nursing interventions in patients receiving Taxan Chemotherapy

• Yeter Kirdal

Liquid Biopsy: Circulating Tumor Cells and its Impact on Follow-up/Treatment of Prostate Cancer Patients

• Ibrahim Kulaç

Molecular Biology in Diagnosis and Treatment of Prostate Cancer

• Ece Konaç
• Sinan Sözen

Current Situation in the Use of 5-Alpha Reductase Inhibitors for Prostatic Diseases

• Murat Kosan

The Effects of Hormonal Therapy on Quality of Life in Prostate Cancer

• Yusuf Senoglu
• Kamil Çam

Article - Comment

Pathological characteristics of prostate cancer detected through prostate specific antigen based screening

• Sinan Ekici

Management and survival of screen-detected prostate cancer patients who might have been suitable for active surveillance

• Kadir Baykal
• Cüneyt Adayener

Time to prostate spesific antigen recurrence after radical prostatectomy and risk of prostate cancer specific mortality

• Mustafa Kaplan

Under diagnosis and over diagnosis of prostate cancer

• Mustafa Kaplan

Finasterid improves the sensitivity of digital rectal examination for prostate cancer detection

• Ahmet Soylu

Long-term survival in men with high grade prostate cancer: a comparison between conservative treatment, radiation therapy and radical prostatectomy—a propensity scoring approach

• Cemil Uygur

Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study

• Kadir Baykal
• Hasan Soydan

Quality of life, sexual function and decisional regret at 1 year after surgical treatment for localized prostate cancer

• Recep Büyükalpelli

Phase-II study of docetaxel, estramustine phosphate, and carboplatin in patients with hormone-refractory prostate cancer

• Ahmet Tunçkiran
• Murat Bozlu

Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911.

• Kadir Türkölmez

Is There Evidence of a Relationship between Benign Prostatic Hyperplasia and Prostate Cancer? Findings of a Literature Review

• Oguz Acar

Prediction of Response to Androgen Deprivation Therapy and Castration Resistance in Primary Metastatic Prostate Cancer

• Ali F. Sahin

Bph

Statin's role on protection from the benign prostatic hyperplasia and prostate cancer

• Eray Hasirci
• A. Ibrahim Oguzülgen

Pathology

Prostate cancer: New developments in pathogenesis and prognostic repercussions

• Bora Gürel